The purpose of this study is to evaluate the effects of tricaprilin (20 g twice a day) on
cognition, activities of daily living, resource utilisation, safety and tolerability, in
subjects with mild to moderately severe probable AD.
This is a randomised, double-blind, placebo-controlled, parallel-group, multi-centre design
in up to 535 participants.